Drug Trial Radar · NCT07920809
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Sep 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, Phase Ib study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HSK60002 tablets in approximately 60 participants with moderate-to-severe atopic dermatitis (AD). Participants are randomized within one of three dose groups in a 4:1 ratio to HSK60002 or matching placebo. Treatment is given orally for up to 16 weeks (Stage 1: Weeks 1-4; Stage 2: Weeks 5-16), followed by a safety follow-up visit approximately 2 weeks after the last dose.
Conditions
- Dermatitis Atopic
Interventions
HSK60002 tabletsDrug
HSK60002 tablets, oral administration.
HSK60002 PlaceboDrug
Placebo tablets, oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI)Time frame: From first dose (Day 1) through Week 16 (end of treatment) and the safety follow-up visit approximately 2 weeks after the last dose.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.